Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through ...

Global Premiere Set for Rare Disease Day, Feb. 28, 2025ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals ...

Pharmaceuticals has closed a royalty financing agreement with Castle Creek Biosciences to support the Phase 3 clinical study of ...

Erica Sciascia is raising awareness about her daughter’s rare diagnosis of epidermolysis bullosa - even the slightest touch ...

Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the ...

Quoin Pharmaceuticals (QNRX) announced the launch of the first episode in its “Living with Netherton” video series dedicated to giving voice to ...

Oleogel-S10 is an effective and well-tolerated long-term treatment for epidermolysis bullosa, including patients with severe forms of the disease.

A Dublin girl born with the most severe form of butterfly skin is excited as she prepares to go to secondary school.

Carol Schober-Flores, BSN, RN, is a Mohs Surgical Nurse and Epidermolysis Bullosa Nurse Specialist, University Hospital, Denver, CO. Topical ointments can be applied directly over the Mepitel ...

A brave young girl battling a horrendous skin condition is excited ahead of going to secondary school. Casey Connors suffers ...